Professor Nash is the principal investigator in a new clinical trial being run by biotherapeutics company Servatus, also based on the Sunshine Coast.
The company has been delving deep into the gut microbiome, which is home to trillions of microbes — including bacteria.
Some microbes are helpful but others can be harmful, triggering disease.
Servatus chief executive Wayne Finlayson said they were using a “consortium” of bacteria to treat immune diseases in the trial.
“They’re actually live bacteria common to your immune system and your body,” Dr Finlayson said.
“We’re developing these drugs to modulate the microbiome and rebalance it … other drugs can be quite nasty and the body tolerates them but after a certain amount of time patients have to switch drugs.
“Hopefully we can provide a much gentler and natural form of treatment.”